CSL Limited Logo

CSL Limited

CMXHF

(2.5)
Stock Price

173,50 USD

19.81% ROA

15.86% ROE

22.25x PER

Market Cap.

95.398.463.140,00 USD

61.14% DER

1.35% Yield

18.08% NPM

CSL Limited Stock Analysis

CSL Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

CSL Limited Fundamental Stock Analysis
# Analysis Rating
1 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

2 Revenue Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 ROE

ROE in an average range (14.45%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 DER

The stock maintains a fair debt to equity ratio (77%), indicating a reasonable balance between the money it owes and the ownership it possesses.

6 Dividend

Investors can rely on the company's consistent dividend payments over the past three years, offering a steady stream of returns.

7 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (755) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 PBV

The stock's high Price-to-Book Value (P/BV) ratio (5.06x) suggests it's overvalued, potentially making it an expensive investment.

9 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

10 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

CSL Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

CSL Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

CSL Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

CSL Limited Revenue
Year Revenue Growth
1993 167.696.000
1994 192.996.000 13.11%
1995 250.430.000 22.93%
1996 281.102.016 10.91%
1997 318.098.008 11.63%
1998 0 0%
1999 0 0%
2000 0 0%
2001 843.308.000 100%
2002 756.585.970 -11.46%
2003 878.656.712 13.89%
2004 1.156.636.673 24.03%
2005 2.096.817.336 44.84%
2006 2.114.029.177 0.81%
2007 2.690.752.332 21.43%
2008 3.402.820.485 20.93%
2009 3.730.499.241 8.78%
2010 3.786.870.352 1.49%
2011 4.475.508.197 15.39%
2012 4.536.913.850 1.35%
2013 4.950.400.000 8.35%
2014 5.334.800.000 7.21%
2015 5.458.600.000 2.27%
2016 5.909.500.000 7.63%
2017 6.615.800.000 10.68%
2018 7.587.900.000 12.81%
2019 8.509.900.000 10.83%
2020 9.100.500.000 6.49%
2021 10.265.300.000 11.35%
2022 10.493.100.000 2.17%
2023 13.174.000.000 20.35%
2024 27.042.711.108 51.28%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

CSL Limited Research and Development Expenses
Year Research and Development Expenses Growth
1993 18.981.000
1994 24.004.000 20.93%
1995 27.097.000 11.41%
1996 30.197.000 10.27%
1997 36.566.000 17.42%
1998 0 0%
1999 0 0%
2000 0 0%
2001 81.208.000 100%
2002 52.514.919 -54.64%
2003 61.672.236 14.85%
2004 70.745.502 12.83%
2005 111.111.873 36.33%
2006 119.486.947 7.01%
2007 161.871.077 26.18%
2008 215.383.511 24.85%
2009 251.489.007 14.36%
2010 269.172.651 6.57%
2011 347.504.435 22.54%
2012 363.305.155 4.35%
2013 426.800.000 14.88%
2014 466.400.000 8.49%
2015 462.700.000 -0.8%
2016 613.800.000 24.62%
2017 645.300.000 4.88%
2018 702.400.000 8.13%
2019 831.800.000 15.56%
2020 921.800.000 9.76%
2021 1.001.400.000 7.95%
2022 1.156.200.000 13.39%
2023 1.235.000.000 6.38%
2024 3.079.020.288 59.89%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

CSL Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 11.871.000
1994 0 0%
1995 0 0%
1996 0 0%
1997 2.359.000 100%
1998 0 0%
1999 0 0%
2000 0 0%
2001 90.190.000 100%
2002 57.589.235 -56.61%
2003 62.073.821 7.22%
2004 91.608.812 32.24%
2005 133.119.071 31.18%
2006 363.390.273 63.37%
2007 162.954.198 -123%
2008 240.763.100 32.32%
2009 328.682.570 26.75%
2010 202.575.957 -62.25%
2011 229.632.558 11.78%
2012 235.892.502 2.65%
2013 280.000.000 15.75%
2014 291.600.000 3.98%
2015 287.500.000 -1.43%
2016 408.300.000 29.59%
2017 484.800.000 15.78%
2018 514.800.000 5.83%
2019 574.800.000 10.44%
2020 691.800.000 16.91%
2021 731.700.000 5.45%
2022 688.000.000 -6.35%
2023 1.086.000.000 36.65%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

CSL Limited EBITDA
Year EBITDA Growth
1993 21.007.207
1994 24.351.320 13.73%
1995 44.636.909 45.45%
1996 58.358.533 23.51%
1997 39.665.099 -47.13%
1998 40.710.689 2.57%
1999 47.395.895 14.11%
2000 68.226.759 30.53%
2001 69.006.904 1.13%
2002 170.614.795 59.55%
2003 172.328.383 0.99%
2004 285.508.735 39.64%
2005 650.844.084 56.13%
2006 243.113.785 -167.71%
2007 778.791.348 68.78%
2008 1.094.152.371 28.82%
2009 1.289.173.418 15.13%
2010 1.320.891.514 2.4%
2011 1.473.496.783 10.36%
2012 1.460.793.745 -0.87%
2013 1.716.700.000 14.91%
2014 1.852.200.000 7.32%
2015 1.954.900.000 5.25%
2016 1.847.800.000 -5.8%
2017 1.941.200.000 4.81%
2018 2.686.300.000 27.74%
2019 2.893.200.000 7.15%
2020 3.143.300.000 7.96%
2021 3.629.200.000 13.39%
2022 3.464.900.000 -4.74%
2023 3.902.000.000 11.2%
2024 6.627.996.332 41.13%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

CSL Limited Gross Profit
Year Gross Profit Growth
1993 167.696.000
1994 192.996.000 13.11%
1995 250.430.000 22.93%
1996 281.102.016 10.91%
1997 318.098.008 11.63%
1998 0 0%
1999 0 0%
2000 0 0%
2001 369.309.000 100%
2002 297.945.615 -23.95%
2003 326.115.813 8.64%
2004 408.527.522 20.17%
2005 810.655.138 49.61%
2006 850.295.336 4.66%
2007 1.217.009.330 30.13%
2008 1.557.561.638 21.86%
2009 1.793.804.274 13.17%
2010 1.930.031.020 7.06%
2011 2.200.244.747 12.28%
2012 2.189.553.186 -0.49%
2013 2.559.000.000 14.44%
2014 2.730.800.000 6.29%
2015 2.852.700.000 4.27%
2016 2.874.700.000 0.77%
2017 3.289.000.000 12.6%
2018 4.056.300.000 18.92%
2019 4.748.700.000 14.58%
2020 5.176.100.000 8.26%
2021 5.798.600.000 10.74%
2022 5.663.500.000 -2.39%
2023 6.708.000.000 15.57%
2024 12.316.081.164 45.53%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

CSL Limited Net Profit
Year Net Profit Growth
1993 9.245.763
1994 8.038 -114939.98%
1995 -4.971 261.68%
1996 0 0%
1997 26.490.625 100%
1998 27.845.272 4.86%
1999 31.629.751 11.96%
2000 32.480.745 2.62%
2001 39.926.414 18.65%
2002 69.703.862 42.72%
2003 47.451.014 -46.9%
2004 153.550.628 69.1%
2005 416.718.516 63.15%
2006 87.084.638 -378.52%
2007 457.420.695 80.96%
2008 671.445.929 31.88%
2009 924.824.870 27.4%
2010 894.829.388 -3.35%
2011 1.005.280.764 10.99%
2012 1.005.587.735 0.03%
2013 1.216.300.000 17.32%
2014 1.307.000.000 6.94%
2015 1.379.000.000 5.22%
2016 1.242.400.000 -10.99%
2017 1.337.400.000 7.1%
2018 1.728.900.000 22.64%
2019 1.918.700.000 9.89%
2020 2.102.500.000 8.74%
2021 2.375.000.000 11.47%
2022 2.254.700.000 -5.34%
2023 2.194.000.000 -2.77%
2024 3.002.044.780 26.92%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

CSL Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 1 0%
2006 0 0%
2007 1 0%
2008 1 100%
2009 2 0%
2010 2 0%
2011 2 0%
2012 2 0%
2013 2 50%
2014 3 0%
2015 3 0%
2016 3 0%
2017 3 0%
2018 4 33.33%
2019 4 25%
2020 5 0%
2021 5 20%
2022 5 -25%
2023 5 0%
2024 6 33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

CSL Limited Free Cashflow
Year Free Cashflow Growth
1993 -16.634.216
1994 2.004.042 930.03%
1995 19.099.614 89.51%
1996 44.200.508 56.79%
1997 45.331.878 2.5%
1998 -13.136.706 445.08%
1999 -26.049.051 49.57%
2000 -22.191.773 -17.38%
2001 97.956.112 122.65%
2002 83.435.410 -17.4%
2003 -74.546.533 211.92%
2004 145.668.832 151.18%
2005 480.885.104 69.71%
2006 425.242.761 -13.08%
2007 -176.335.573 341.16%
2008 481.254.810 136.64%
2009 768.260.259 37.36%
2010 916.748.490 16.2%
2011 791.316.529 -15.85%
2012 841.826.555 6%
2013 964.131.805 12.69%
2014 1.042.579.830 7.52%
2015 1.361.720.833 23.44%
2016 1.021.426.312 -33.32%
2017 760.044.825 -34.39%
2018 909.500.000 16.43%
2019 359.600.000 -152.92%
2020 1.120.700.000 67.91%
2021 1.954.800.000 42.67%
2022 1.381.000.000 -41.55%
2023 909.000.000 -51.93%
2024 1.150.382.827 20.98%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

CSL Limited Operating Cashflow
Year Operating Cashflow Growth
1993 14.578.000
1994 38.371.000 62.01%
1995 41.368.000 7.24%
1996 56.972.984 27.39%
1997 57.859.008 1.53%
1998 0 0%
1999 0 0%
2000 0 0%
2001 129.038.000 100%
2002 130.085.000 0.8%
2003 0 0%
2004 206.994.000 100%
2005 567.822.000 63.55%
2006 522.164.000 -8.74%
2007 480.840.000 -8.59%
2008 715.336.000 32.78%
2009 1.024.824.000 30.2%
2010 1.168.492.000 12.3%
2011 1.018.119.000 -14.77%
2012 1.160.000.000 12.23%
2013 1.414.231.805 17.98%
2014 1.444.479.830 2.09%
2015 1.775.520.833 18.64%
2016 1.587.126.312 -11.87%
2017 1.620.644.825 2.07%
2018 1.902.100.000 14.8%
2019 1.644.400.000 -15.67%
2020 2.488.300.000 33.91%
2021 3.621.900.000 31.3%
2022 2.628.700.000 -37.78%
2023 2.601.000.000 -1.06%
2024 1.707.327.780 -52.34%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

CSL Limited Capital Expenditure
Year Capital Expenditure Growth
1993 31.212.216
1994 36.366.958 14.17%
1995 22.268.385 -63.31%
1996 12.772.475 -74.35%
1997 12.527.130 -1.96%
1998 13.136.706 4.64%
1999 26.049.051 49.57%
2000 22.191.773 -17.38%
2001 31.081.888 28.6%
2002 46.649.589 33.37%
2003 74.546.533 37.42%
2004 61.325.167 -21.56%
2005 86.936.896 29.46%
2006 96.921.239 10.3%
2007 657.175.573 85.25%
2008 234.081.189 -180.75%
2009 256.563.741 8.76%
2010 251.743.509 -1.91%
2011 226.802.471 -11%
2012 318.173.445 28.72%
2013 450.100.000 29.31%
2014 401.900.000 -11.99%
2015 413.800.000 2.88%
2016 565.700.000 26.85%
2017 860.600.000 34.27%
2018 992.600.000 13.3%
2019 1.284.800.000 22.74%
2020 1.367.600.000 6.05%
2021 1.667.100.000 17.97%
2022 1.247.700.000 -33.61%
2023 1.692.000.000 26.26%
2024 556.944.953 -203.8%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

CSL Limited Equity
Year Equity Growth
1993 104.760.155
1994 231.322.202 54.71%
1995 235.253.009 1.67%
1996 268.975.618 12.54%
1997 273.590.763 1.69%
1998 242.273.858 -12.93%
1999 276.980.275 12.53%
2000 473.807.391 41.54%
2001 447.001.729 -6%
2002 716.772.322 37.64%
2003 864.281.864 17.07%
2004 1.450.064.671 40.4%
2005 1.581.809.863 8.33%
2006 1.476.531.960 -7.13%
2007 1.924.384.223 23.27%
2008 2.684.747.562 28.32%
2009 4.408.831.552 39.11%
2010 3.582.368.588 -23.07%
2011 3.894.961.845 8.03%
2012 3.508.504.410 -11.01%
2013 3.006.800.000 -16.69%
2014 3.161.999.999 4.91%
2015 2.746.900.000 -15.11%
2016 2.567.200.000 -7%
2017 3.163.800.000 18.86%
2018 4.079.900.000 22.45%
2019 5.251.300.000 22.31%
2020 6.527.400.000 19.55%
2021 8.381.300.000 22.12%
2022 14.577.500.000 42.51%
2023 17.826.000.000 18.22%
2024 19.364.687.578 7.95%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

CSL Limited Assets
Year Assets Growth
1993 153.075.129
1994 312.671.805 51.04%
1995 335.456.127 6.79%
1996 373.815.592 10.26%
1997 385.179.652 2.95%
1998 325.150.388 -18.46%
1999 374.853.467 13.26%
2000 565.095.826 33.67%
2001 904.155.376 37.5%
2002 1.301.723.904 30.54%
2003 1.495.524.620 12.96%
2004 2.709.470.674 44.8%
2005 2.954.140.360 8.28%
2006 3.106.279.960 4.9%
2007 3.562.081.424 12.8%
2008 4.491.885.841 20.7%
2009 5.945.390.935 24.45%
2010 4.853.647.218 -22.49%
2011 5.416.494.239 10.39%
2012 5.955.441.390 9.05%
2013 5.975.500.000 0.34%
2014 6.277.700.000 4.81%
2015 6.401.000.000 1.93%
2016 7.562.699.999 15.36%
2017 9.122.700.000 17.1%
2018 10.774.500.000 15.33%
2019 12.314.400.000 12.5%
2020 15.464.599.999 20.37%
2021 18.156.900.000 14.83%
2022 28.346.000.000 35.95%
2023 36.234.000.000 21.77%
2024 37.950.835.067 4.52%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

CSL Limited Liabilities
Year Liabilities Growth
1993 48.314.974
1994 81.349.603 40.61%
1995 100.203.117 18.82%
1996 104.839.979 4.42%
1997 111.588.894 6.05%
1998 82.876.529 -34.64%
1999 97.873.192 15.32%
2000 91.288.435 -7.21%
2001 457.153.646 80.03%
2002 584.951.582 21.85%
2003 631.242.756 7.33%
2004 1.259.406.002 49.88%
2005 1.372.330.496 8.23%
2006 1.629.748.000 15.79%
2007 1.637.697.201 0.49%
2008 1.807.138.278 9.38%
2009 1.536.559.382 -17.61%
2010 1.271.278.630 -20.87%
2011 1.521.532.394 16.45%
2012 2.446.936.979 37.82%
2013 2.968.700.000 17.58%
2014 3.115.699.999 4.72%
2015 3.654.100.000 14.73%
2016 4.995.499.999 26.85%
2017 5.958.899.999 16.17%
2018 6.694.599.999 10.99%
2019 7.063.100.000 5.22%
2020 8.937.200.000 20.97%
2021 9.775.600.000 8.58%
2022 13.768.499.999 29%
2023 18.408.000.000 25.2%
2024 18.586.147.488 0.96%

CSL Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
51.91
Net Income per Share
8.86
Price to Earning Ratio
22.25x
Price To Sales Ratio
3.8x
POCF Ratio
19.25
PFCF Ratio
36.56
Price to Book Ratio
5.49
EV to Sales
4.22
EV Over EBITDA
13.98
EV to Operating CashFlow
21.41
EV to FreeCashFlow
40.58
Earnings Yield
0.04
FreeCashFlow Yield
0.03
Market Cap
95,40 Bil.
Enterprise Value
105,90 Bil.
Graham Number
84.53
Graham NetNet
-24.59

Income Statement Metrics

Net Income per Share
8.86
Income Quality
1.16
ROE
0.22
Return On Assets
0.07
Return On Capital Employed
0.12
Net Income per EBT
0.78
EBT Per Ebit
0.91
Ebit per Revenue
0.25
Effective Tax Rate
0.2

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.49
Operating Profit Margin
0.25
Pretax Profit Margin
0.23
Net Profit Margin
0.18

Dividends

Dividend Yield
0.01
Dividend Yield %
1.35
Payout Ratio
0.48
Dividend Per Share
2.66

Operating Metrics

Operating Cashflow per Share
10.24
Free CashFlow per Share
5.4
Capex to Operating CashFlow
0.47
Capex to Revenue
0.09
Capex to Depreciation
1.44
Return on Invested Capital
0.17
Return on Tangible Assets
0.2
Days Sales Outstanding
40.18
Days Payables Outstanding
94.37
Days of Inventory on Hand
168.25
Receivables Turnover
9.08
Payables Turnover
3.87
Inventory Turnover
2.17
Capex per Share
4.84

Balance Sheet

Cash per Share
3,42
Book Value per Share
40,07
Tangible Book Value per Share
6.25
Shareholders Equity per Share
35.86
Interest Debt per Share
23.42
Debt to Equity
0.61
Debt to Assets
0.28
Net Debt to EBITDA
1.39
Current Ratio
2.18
Tangible Asset Value
3,02 Bil.
Net Current Asset Value
-7,84 Bil.
Invested Capital
31793033914
Working Capital
5,81 Bil.
Intangibles to Total Assets
0.43
Average Receivables
3,16 Bil.
Average Payables
3,11 Bil.
Average Inventory
5753015329.5
Debt to Market Cap
0.11

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

CSL Limited Dividends
Year Dividends Growth
2014 1
2015 1 0%
2016 1 100%
2017 1 0%
2018 1 0%
2019 1 100%
2021 2 50%
2022 1 -100%
2023 2 50%
2024 3 0%

CSL Limited Profile

About CSL Limited

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

CEO
Dr. Paul F. McKenzie Ph.D.
Employee
32.698
Address
45 Poplar Road
Parkville, 3052

CSL Limited Executives & BODs

CSL Limited Executives & BODs
# Name Age
1 Mr. Gregory Boss B.S., BS(Hons), J.D.
Executive Vice President of Legal & General Counsel
70
2 Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D.
Senior Vice President of Research
70
3 Ms. Roanne Parry
Chief Human Resources Officer
70
4 Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI
Interim Executive Vice President of CSL Behring
70
5 Mr. John A. G. Levy CPA
Interim Chief Financial Officer
70
6 Mr. Mark Hill B.A., M.B.A.
Chief Digital Information Officer & Executive Vice President
70
7 Chris Cooper
Head of Investor Relations
70
8 Dr. Paul F. McKenzie Ph.D.
MD, Chief Executive Officer & Executive Director
70
9 Mr. Andy Schmeltz
Executive Vice President of CSL Behring Business Unit (Leave of Absence)
70
10 Dr. William Mezzanotte M.D., M.P.H.
Executive Vice President & Head of Research and Development
70

CSL Limited Competitors